Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,440.10 15.25 0.09%
S&P 500 1,865.88 3.57 0.19%
NASDAQ 4,103.52 17.30 0.42%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,417.53 -0.15 -0.00%
TOPIX 1,166.59 0.04 0.00%
HANG SENG 22,760.24 64.23 0.28%

CytoSorbents to Present at the Rodman & Renshaw Annual Global Investment Conference


CytoSorbents to Present at the Rodman & Renshaw Annual Global Investment Conference

MONMOUTH JUNCTION, NJ -- (Marketwired) -- 08/28/13 -- CytoSorbents Corporation (OTCBB: CTSO), a critical care focused company commercializing its European Union approved CytoSorb(R) blood filter to treat life-threatening illnesses in the intensive care unit, President and Chief Executive Officer, Dr. Phillip Chan will present at the Rodman & Renshaw Annual Global Investment Conference taking place on September 8-10 in New York City.

Conference Presentation Details: Where: Millennium Broadway Hotel, 145 W 44th Street, New York, NY 10036 When: Monday, September 9th at 12:30 p.m. Room: 7.03 Webcast: http://wsw.com/webcast/rrshq23/CTSO Conference Website: www.rodm.com

About CytoSorbents Corporation CytoSorbents is a critical care focused therapeutic device company using blood purification to modulate the immune system -- with the goal of preventing or treating multiple organ failure in life-threatening illnesses. Organ failure is the cause of nearly half of all deaths in the intensive care unit, with little to improve clinical outcome. CytoSorb(R), the Company's flagship product, is approved in the European Union as a safe and effective extracorporeal cytokine filter, designed to reduce the "cytokine storm" that could otherwise cause massive inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury, and pancreatitis. These are conditions where the mortality is extremely high, yet no effective treatments exist. CytoSorbents' purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. CytoSorbents has numerous products under development based upon this unique blood purification technology, protected by 32 issued US patents and multiple applications pending, including HemoDefend(TM), ContrastSorb, DrugSorb, and others. Additional information is available for download on the Company's website: http://www.cytosorbents.com

Company Contact: CytoSorbents Corporation Dr. Phillip Chan Chief Executive Officer (732) 329-8885 ext. *823 pchan@cytosorbents.com

Investor Contact: Alliance Advisors, LLC Alan Sheinwald (914) 669-0222 asheinwald@allianceadvisors.net

Valter Pinto (914) 669-0222 x201 valter@allianceadvisors.net

Media Contact: JQA Partners Jules Abraham (917) 885-7378 jabraham@jqapartners.com

Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement